Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare ConferenceGlobeNewsWire • 06/06/23
Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease ConferenceGlobeNewsWire • 03/29/23
Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 03/06/23
Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care ConferenceGlobeNewsWire • 02/27/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDAPRNewsWire • 02/07/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Entrada Therapeutics, Inc. - TRDANewsfile Corp • 01/07/23
Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular DystrophyGlobeNewsWire • 12/19/22
Entrada Skyrockets On $250 Million Deal With Vertex In Muscular DystrophyInvestors Business Daily • 12/08/22
Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)Business Wire • 12/08/22
Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 08/30/22
Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs OfficerGlobeNewsWire • 07/19/22
Entrada Therapeutics to Present at Goldman Sachs Global Healthcare ConferenceGlobeNewsWire • 06/01/22
Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV™) Therapeutics at TIDES USA 2022GlobeNewsWire • 05/11/22